Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Potential Link Between Industrial Pollutants and Acute Myeloid Leukemia Examined

March 8, 2019
By John Schieszer
News
Article

A recent study evaluated whether living in an industrial city could be an important risk factor for developing AML.

Living in an industrial city with exposure to materials/pollution from industrial plants may be an important risk factor for developing acute myeloid leukemia (AML), according to a study published online in the journal Cancer.

Feras M. Ghazawi, MD, PhD, of the University of Ottawa in Ontario, Canada, and colleagues analyzed the incidence and geographic distribution of AML in Canada from 1992 to 2010 using three independent population‐based cancer registries. A total of 18,085 patients were identified during this timeframe, with an AML incidence of 30.61 cases per million individuals per year. The incidence and mortality rates were then examined at the levels of province/territory, city, and postal code.

Five industrial cities in Ontario had incidence rates that were significantly higher than the national average (Sarnia, Sault Ste. Marie, Thunder Bay, St. Catharines, and Hamilton). In one specific postal code in Sarnia, Ontario, the incidence rate was 106.81 cases per million individuals per year, which is more than three times higher than the national average.

“The pollution from local oil refineries and chemical plants in Sarnia may be implicated as a risk factor for AML in that city. Analysis of mortality rates at the province and city levels corroborated the findings from the incidence data,” concluded the authors.

Felipe Samaniego, MD, an associate professor of Lymphoma/Myeloma at MD Anderson Cancer Center in Houston, said this report independently reaches the conclusion that industry centers are associated with the emergence of a higher number of AML cases. However, in some ways it raises more questions than answers, he said.

“It is an area of immensely important and fruitful research. We now have the capacity to look at sum experiences of all studies that identify hotspots of cancers and analyze what is common to most areas that leads to a high incidence of AML,” Samaniego told Cancer Network. “The report implies that pollution is the culprit for AML; however, pollution may be only an associated factor and the real culprit is another factor associated with industry activity.”

Until now, several risk factors have been implicated in AML leukemogenesis, but the epidemiologic distribution and precise triggers for AML in Canada had not been fully investigated, the researchers noted.

Recent Videos
The medical characteristics of a patient may heavily factor into the selection of tyrosine kinase inhibition for the treatment of chronic myeloid leukemia.
The toxicity profile of interferon and the limited availability of transplantation established a need for TKI development for chronic myeloid leukemia.
Related Content
Advertisement

The second takeaway is that the type of responses and efficacy that we have seen with these combinations rival what we have in our standard of care armamentarium.

How Promising Are Immunotherapy Combos in Indolent Lymphoma?

Tim Cortese
September 12th 2025
Article

Lorenzo Falchi, MD, highlighted the most important considerations when using novel immunotherapy combination therapies for patients with indolent lymphoma.


A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.


Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML

Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML

Tim Cortese
September 11th 2025
Article

Ziftomenib yielded a median overall survival of 16.4 months in responders with NPM1-mutant AML who received ziftomenib in the phase 1b/2 KOMET-001 trial.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


The overall safety profile of pirtobrutinib was consistent with previously reported trials across various CLL and SLL settings.

Pirtobrutinib Improves PFS in Treatment-Naïve CLL/SLL Without 17p Deletions

Tim Cortese
September 8th 2025
Article

Results from the phase 3 BRUIN CLL-313 trial show that OS trended favorably for pirtobrutinib vs chemoimmunotherapy in this CLL and SLL population.


The safety and cytokine release syndrome profiles of mosunetuzumab were manageable in patients with previously untreated marginal zone lymphoma.

Mosunetuzumab Exhibits Meaningful Responses in Untreated MZL

Roman Fabbricatore
September 5th 2025
Article

The safety and cytokine release syndrome profiles of mosunetuzumab were manageable in patients with previously untreated marginal zone lymphoma.

Related Content
Advertisement

The second takeaway is that the type of responses and efficacy that we have seen with these combinations rival what we have in our standard of care armamentarium.

How Promising Are Immunotherapy Combos in Indolent Lymphoma?

Tim Cortese
September 12th 2025
Article

Lorenzo Falchi, MD, highlighted the most important considerations when using novel immunotherapy combination therapies for patients with indolent lymphoma.


A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.


Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML

Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML

Tim Cortese
September 11th 2025
Article

Ziftomenib yielded a median overall survival of 16.4 months in responders with NPM1-mutant AML who received ziftomenib in the phase 1b/2 KOMET-001 trial.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


The overall safety profile of pirtobrutinib was consistent with previously reported trials across various CLL and SLL settings.

Pirtobrutinib Improves PFS in Treatment-Naïve CLL/SLL Without 17p Deletions

Tim Cortese
September 8th 2025
Article

Results from the phase 3 BRUIN CLL-313 trial show that OS trended favorably for pirtobrutinib vs chemoimmunotherapy in this CLL and SLL population.


The safety and cytokine release syndrome profiles of mosunetuzumab were manageable in patients with previously untreated marginal zone lymphoma.

Mosunetuzumab Exhibits Meaningful Responses in Untreated MZL

Roman Fabbricatore
September 5th 2025
Article

The safety and cytokine release syndrome profiles of mosunetuzumab were manageable in patients with previously untreated marginal zone lymphoma.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.